Summary
Molecular classification of diffuse large B-cell lymphoma (DLBCL) is a critical biologic, prognostic, and predictive distinction. Since the discovery of two molecular types of DLBCL in otherwise morphologically indistinguishable cases, numerous methodologies for making this distinction have been published. A method and technical platform may now be reaching consensus.
Research. biopsies. This model was applied using the Nanostring nCounter system (Seattle, WA) to identify the DLBCL subgroups. Additionally, they compared DLBCL type between time of diagnosis and matched relapsed biopsies in 18 patients suggesting that type remains consistent in most cases. Arriving at an accurate consensus methodology in the cell of origin distinction is crucial for moving forward DLBCL patient management and its significance cannot be over- In 2004, the first of several IHC assays was described in response to the desire for an inexpensive, relatively low-tech method useful for studies using FFPE tissues (FFPET) such as those processed in routine clinical practice (6) . Subsequently, several other IHC studies based on additional antibodies and cut-points were reported with agreement between IHC and GEP of 83-93% (7, 8) . A draw-back to the IHC studies, however, is the dichotomous distinction between GCB and non-GCB, with the latter category presumably including both ABC-DLBCL and UNC- In the meantime, biological studies continued to emphasize the substantial genomic, genetic, epi-genetic, microRNA and other differences between the types such that the relationship between the "types" is more like two separate diseases rather than subtypes of the same disease. Identification of different mutational profiles in addition to the over-expressed signaling pathways spawned efforts for differential therapy. In at least 2 completed and published studies, the molecular type became not only a prognostic, but also a predictive distinction, with many more studies underway with drugs such as ibrutinib, bortezomib, and lenalidomide.
Given the diagnostic, prognostic, and predictive significance of the COO distinction, an accurate, reliable, and widely-accepted assay for the field is of utmost importance. Such an assay should be applicable to FFPET, sensitive, specific, and reproducible between laboratories and operators. The assay should be able to both accommodate phenotypic variations within types and result in two categories as well as identifying patients where the confidence is low (UNC-DLBCL). Multi-analyte, multiplexed molecular assays are more likely than IHC to have the breadth of reagents needed to make these distinctions accurately. Furthermore, the assay must be forgiving of the partially degraded mRNA characteristically found in FFPET, not technically burdensome, and standardizable. 
between the various platforms previously used to classify DLBCL. While IHC may be the least expensive and most suitable for low tumor content samples, the cost is offset by the lower accuracy and binary results. The nCounter system appears to fulfill all needed criteria due to its demonstrated utility in FFPET, documented inter-laboratory reproducibility, and FDA-clearance of the platform for the ProSigna breast cancer assay.
In February 2014, Scott and colleagues described the "Lymph2Cx" assay for classification of DLBCL using the Nanostring nCounter system ( based studies indicate that this non-enzymatic, solution phase hybridization, fluorescent barcode-labeled method, can become the tool needed to move our biologic knowledge of DLBCL into a robust assay for appropriately selecting ABC or GCB patients for well designed clinical trials. After nearly a decade and a half, to paraphrase an old saying, the molecular classification of DLBCL can now be tied up with a "string."
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